Golden
CytomX Therapeutics

CytomX Therapeutics

A biotechnology company that develops Probodies, proteolytically-activated antibodies to treat cancer.

All edits

Edits a day ago
Golden AI
Golden AI edited a day ago
Edits made to:
Infobox (+1 properties)
Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 9:52 pm
Edits made to:
Infobox (+1 properties)
Edits on 4 Jun 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 4 Jun 2019 3:33 am
Edits made to:
Article (+17/-17 characters)

Article

CytomX Therapeutics is a privately funded and publicly traded biotechnology company based in the South San Francisco, California and was founded in 2008 by Fred Gluck and Patrick DaughertyPatrick Daugherty. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

Edits on 3 Jun 2019
Golden AI
Golden AI edited on 3 Jun 2019 12:59 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 30 Mar 2019
Dawson Sewell
Dawson Sewell edited on 30 Mar 2019 1:09 am
Edits made to:
Infobox (+1 properties)
Article (+106/-24 characters)
Further reading (+1 rows) (+4 cells) (+219 characters)

Article

CytomX Therapeutics is a privately funded and publicly traded biotechnology company based in the South San FranciscoSan Francisco,  BayCalifornia  Areaand was founded in 2008 by Fred Gluck and Patrick Daugherty. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

Further reading

Title
Author
Link
Type

CytomX Therapeutics Announces Senior Management Appointments

CytomX Therapeutics Inc.

Web

Infobox

Dawson Sewell
Dawson Sewell edited on 30 Mar 2019 1:04 am
Edits made to:
Infobox (+8/-2 properties)
Categories (-1 topics)
Related Topics (+1 topics)
Topic thumbnail

CytomX Therapeutics

A biotechnology company that develops Probodies, proteolytically-activated antibodies to treat cancer.

Infobox

Categories

Related Topics

Edits on 8 Feb 2019
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 8 Feb 2019 12:21 pm
Edits made to:
People (+3 rows) (+6 cells) (+63 characters)

People

Name
Role
Related Golden topics

Eric Kanowsky

Investor



George Holbrook

Investor



John Petote

Investor



Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:15 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox

Edits on 9 Jan 2019
Golden AI
Golden AI edited on 9 Jan 2019 9:59 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 17 Dec 2018
Carla Faraguna
Carla Faraguna edited on 17 Dec 2018 9:31 pm
Edits made to:
Description (+1 characters)
Categories (+1/-1 topics)
Topic thumbnail

CytomX Therapeutics

A biotechnology company that develops Probodies, proteolytically-activated antibodies to treat cancer.

Categories

Edits on 17 Dec 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 Dec 2018 5:16 pm
Edits made to:
Article (+14/-14 characters)

Article

All products, except CX-188 are in various Phase 1/2 clinical trialclinical trial progression. CX-2009 is currently being evaluated in its clinical trial, while CX-2009 and BMS-986249 are enrolling patients for the clinical studies.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 Dec 2018 5:16 pm
Edits made to:
Article (+22/-22 characters)

Article

CytomX Therapeutics is a privately funded and publicly traded company based in the San Francisco Bay AreaSan Francisco Bay Area. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

Sameeha Sulaiman
Sameeha Sulaiman edited on 16 Dec 2018 9:44 pm
Edits made to:
Article (+47/-47 characters)

Article

The company is also collaborating with other biopharmaceutical companies including AbbVieAbbVie, AmgenAmgen, Bristol-Myers Squibb Companyristol-Myers Squibb Company, and ImmunoGenImmunoGen, Inc. BMS-986249 is a CTLA-4 targeting Probody therapeutic partnered with Bristol Myers Squibb. CX-2029 is a DC71 targeting Probody drug conjugate partnered with AbbVie.





Sameeha Sulaiman
Sameeha Sulaiman edited on 16 Dec 2018 9:42 pm
Edits made to:
Infobox (+2/-2 properties)
Article (+1281 characters)
People (+13 rows) (+26 cells) (+567 characters)

Article

CytomX Therapeutics is a privately funded and publicly traded company based in the San Francisco Bay Area. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.



Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. CytomX's product pipeline includes cancer immunotherapies against clinically-validated targets. CX-072 and CX-188 are PD-L1 targeting Probody therapeutic. CX-2009 is an in-class Probody drug conjugate targeting CD166. All three are owned wholly by CytomX.

...

The company is also collaborating with other biopharmaceutical companies including AbbVie, Amgen, Bristol-Myers Squibb Company, and ImmunoGen, Inc. BMS-986249 is a CTLA-4 targeting Probody therapeutic partnered with Bristol Myers Squibb. CX-2029 is a DC71 targeting Probody drug conjugate partnered with AbbVie.



All products, except CX-188 are in various Phase 1/2 clinical trial progression. CX-2009 is currently being evaluated in its clinical trial, while CX-2009 and BMS-986249 are enrolling patients for the clinical studies.

People

Name
Role
Related Golden topics

Alison Joly

Senior VP, Program and Alliance Management



Charles S. Fuchs

Director



Danielle Olander

Senior VP, Talent and Administrative Operations



Debanjan Ray

CFO



Fred Gluck

Co-Founder & Director



Hoyoung Huh

Chairman



John Scarlett

Director



Lloyd A. Rowland, Jr.

Senior VP, General Counsel, Secretary, & Chief Compliance Officer



Matthew Young

Director



Rachel Humphrey

Chief Medical Officer



Sean A. McCarthy

President & CEO



Sridhar Viswanathan

Senior VP, Process Sciences and Manufacturing Operations



W. Michael Kavanaugh

Chief Scientific Officer & Head of Research and Non-Clinical Development



Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:06 am
Edits made to:
Infobox (+3 properties)
People (+3 rows) (+6 cells) (+58 characters)

People

Name
Role
Related Golden topics

Jim West

Employee



Mike Panesis

Investor



Olga Vasiljeva

Employee



Infobox

Edits on 14 Nov 2018
Melanie Manipula"Approved suggestion from source: http://www.cytomx.com"
Melanie Manipula approved a suggestion from Golden's AI on 14 Nov 2018 10:25 pm
Edits made to:
Infobox (+1 properties)
Edits on 18 Sep 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 Sep 2018 7:59 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:53 pm
Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:51 pm

Infobox